biogenesis of lysosomal organelles complex 1 subunit 6Genealiases: BLOS6 · HPS9 · PA · PALLID · PLDN
Q-omics provides the consensus-scored BLOC1S6 profile across patient tissues and cancer cell-line models. BLOC1S6 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BLOC1S6 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, BLOC1S6 protein abundance shows 19,963 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where BLOC1S6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BLOC1S6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BLOC1S6 survival associations across molecular data types. BLOC1S6 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BLOC1S6 RNA expression–survival associations across cancer types. High BLOC1S6 expression shows unfavorable associations in LIHC, BLCA and SCLC, but favorable associations in KIRC, SKCM and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for BLOC1S6 RNA expression.
This table summarizes BLOC1S6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for BLOC1S6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BLOC1S6 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, LIHC, CHOL and STAD. The HNSC box plot shows higher BLOC1S6 RNA expression in tumor versus normal tissue (log2 FC = +1.093, t-test p < 0.001).
This table shows molecular features associated with BLOC1S6 in patient tissues and cancer cell lines. In patient samples, BLOC1S6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, BLOC1S6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
